Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01-Reference-Cited by-同舟云学术

Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01

Published:2018-12 Issue: Volume:291 Page:1-10
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Wilkinson Alexander,Lattmann Eric,Roces Carla B.,Pedersen Gabriel K.,Christensen Dennis^ORCID,Perrie Yvonne

Funder

European Commission

Horizon 2020

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference65 articles.

1. CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in Ferrets;Martel;PLoS One,2011

2. A novel liposome-based adjuvant CAF01 for induction of CD8+ cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice;Gram;PLoS One,2009

3. Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen;Vangala;J. Control. Release,2007

4. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses;Davidsen;Biochim Biophys Acta,2005

5. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen;Henriksen-Lacey;J. Control. Release,2010

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oxygen and pH responsive theragnostic liposomes for early-stage diagnosis and photothermal therapy of solid tumours;Biomaterials Science;2024

2. Liposomes as vaccine delivery systems;Liposomes in Drug Delivery;2024

3. Liposomal delivery system/adjuvant for tuberculosis vaccine;Immunity, Inflammation and Disease;2023-06

4. Formulation and Evaluation of Lipidized Imiquimod as an Effective Adjuvant;ACS Infectious Diseases;2023-01-23

5. SARS-CoV-2 delta (B.1.617.2) spike protein adjuvanted with Alum-3M-052 enhances antibody production and neutralization ability;Frontiers in Public Health;2023-01-06